Trade Resources Industry Views Mylan Pharmaceuticals Has Launched The First Generic Versions of Abbott's Trilipix Capsule

Mylan Pharmaceuticals Has Launched The First Generic Versions of Abbott's Trilipix Capsule

Mylan Pharmaceuticals, Mylan's US subsidiary, has launched one of the first generic versions of Abbott's Trilipix Capsule in the US.

Known as Fenofibric Acid Delayed-release Capsules, 45mg and 135mg is indicated for patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their low-density lipoprotein cholesterol goal.

New generic product is used as an adjunct to diet in combination with a statin to lessen triglyceride and enhance high-density lipoprotein cholesterol.

The US Food and Drug Administration has approved the product's abbreviated new drug application.

The sales of Fenofibric Acid Delayed-release Capsules, 45mg and 135mg, were around $553.6m for the 12 months ending on 31 March 2013 in the US, according to IMS Health data.

 

Source: http://drugdiscovery.pharmaceutical-business-review.com/news/mylan-launches-generic-version-of-abbotts-trilipix-capsule-in-us-160713
Contribute Copyright Policy
Mylan Launches Generic Version of Abbott's Trilipix Capsule in US